Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
Introduction Long-acting injectable (LAI) antipsychotics are a promising solution to combating issues related to nonadherence to oral antipsychotics. Oral overlap is utilized when an LAI is initiated to achieve therapeutic concentrations. The place in therapy in which additional overlap is warranted...
Main Authors: | Tran Jennifer T. PharmD, Binger Katie J. PharmD, BCPP, Miles Talia M. PharmD, BCPS, BCPP |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association of Psychiatric Pharmacists
2023-06-01
|
Series: | Mental Health Clinician |
Subjects: | |
Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2023.06.147 |
Similar Items
-
The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
by: Trevor A. Stump, PharmD, BCPP, et al.
Published: (2021-01-01) -
Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
by: Shaina Schwartz, PharmD, BCPP, et al.
Published: (2023-08-01) -
An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
by: Amy M. VandenBerg, PharmD, BCPP
Published: (2022-11-01) -
Impact of traditional versus nontraditional initiation dosing schedule of paliperidone palmitate on 30-day readmission and safety
by: Erika Kim, PharmD, BCPP, et al.
Published: (2023-12-01) -
Assessment of hepatitis C monitoring adherence after viral eradication in veterans with substance use to improve care and surveil reinfection
by: Miranda L. Stratton, PharmD, et al.
Published: (2022-06-01)